EverSource Wealth Advisors’s Stoke Therapeutics STOK Stock Holding History

EverSource Wealth Advisors’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.16K	Sell	66 -1,771	-96%	-$56.8K	﹤0.01%	3695
2026 Q1	$59.8K	Buy	1,837 +1,215	+195%	+$39.8K	﹤0.01%	1760
2025 Q4	$19.7K	Buy	622 +605	+3,559%	+$18.2K	﹤0.01%	2389
2025 Q3	$400	Sell	17 -1	-6%	-$17	﹤0.01%	4005
2025 Q2	$204	Buy	+18	New	+$171	﹤0.01%	4058
2025 Q1	–	Sell	-3	Closed	-$33	–	4168
2024 Q4	$33	Buy	+3	New	+$37	﹤0.01%	3674
2023 Q3	–	Sell	-127	Closed	-$1.35K	–	2650
2023 Q2	$1.35K	Buy	+127	New	+$1.35K	﹤0.01%	2129

Other funds holding STOK

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

GIM

Generali Investments Management Ljubljana, Slovenia $460M AUM 29.43% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $188M AUM

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

YMRC

Yorktown Management & Research Company Forest, Virginia $163M AUM 68.53% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

EverSource Wealth Advisors's STOK Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its Stoke Therapeutics (STOK) stake by 96% in Q2 2026, selling an estimated $56.8K and leaving 66 shares worth $2.16K. The position accounts for ﹤0.01% of the portfolio, ranked #3695.

EverSource Wealth Advisors first reported a position in STOK in Q2 2023 and has held it in 7 quarters since. The position peaked at $59.8K in Q1 2026. 20 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

EverSource Wealth Advisors held 66 shares of Stoke Therapeutics worth $2.16K as of Q2 2026.
EverSource Wealth Advisors sold 1,771 Stoke Therapeutics shares in Q2 2026, an estimated $56.8K.
Stoke Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3695 holding.
EverSource Wealth Advisors first reported a position in Stoke Therapeutics in Q2 2023 and has held it in 7 quarters since.
EverSource Wealth Advisors's Stoke Therapeutics position peaked at $59.8K in Q1 2026.
20 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.